292
Views
4
CrossRef citations to date
0
Altmetric
Drug Evaluations

Exenatide once weekly in type 2 diabetes mellitus

, MD, , MD FACP FACE & , MD FACP FACE
Pages 1297-1303 | Published online: 06 May 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Irl B. Hirsch, Doron Schneider, Aaron King, William H. Polonsky, Timothy S. Reid, Jay Shubrook, Carol A. Verderese, Jeffrey Wallace & Matthew C. Riddle. (2014) A Short-Acting GLP-1 Analog or Prandial Insulin to Supplement Basal Insulin?—Moving Toward Personalized Management of Type 2 Diabetes Mellitus. Postgraduate Medicine 126:3, pages 135-144.
Read now
Devesh Sennik, Fahad Ahmed & David Russell-Jones. (2012) Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 7:1, pages 15-26.
Read now
Franco Folli & Rodolfo Guardado Mendoza. (2011) Potential use of exenatide for the treatment of obesity. Expert Opinion on Investigational Drugs 20:12, pages 1717-1722.
Read now

Articles from other publishers (1)

I. B. Hirsch, J. B. Buse, J. Leahy, J. B. McGill, A. Peters, H. W. Rodbard, R. R. Rubin, J. S. Skyler, C. A. Verderese & M. C. Riddle. (2014) Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. Diabetes, Obesity and Metabolism 16:3, pages 206-214.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.